Caris Life Sciences (CAI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting opened by CEO, with participation from CFO, General Counsel, and independent auditors present for Q&A.
Shareholders were welcomed and informed about the agenda and voting procedures.
Board and executive committee updates
Ten nominees were presented for election to the board for terms expiring at the 2027 annual meeting.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Caris Life Sciences
- Q2 2026 revenue up 45% to $263.7M, margin at 68%, and guidance raised for the year.CAI
Q2 2026 - Rapid growth in precision oncology, AI-driven innovation, and strong financial performance.CAIGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Rapid growth and innovation in precision oncology, with robust financial and clinical momentum.CAIBank of America Global Healthcare Conference 2026
- Q1 2026 revenue up 79% to $216.2M, gross margin 65%, net loss narrowed, strong outlook.CAIQ1 2026
- Virtual meeting to elect directors and ratify Deloitte as auditor, with strong governance focus.CAIProxy filing
- Election of ten directors and auditor ratification headline the June 2026 annual meeting.CAIProxy filing
- Record 2025 revenue and margin gains; 2026 outlook targets $1B+ revenue and continued growth.CAIQ4 2025
- Record revenue growth, MCED launch, and major partnerships drive transformative expansion.CAI44th Annual J.P. Morgan Healthcare Conference
- IPO targets $364.6M to fund AI-powered oncology solutions; rapid growth, but ongoing losses.CAIRegistration Filing